Bright Minds Biosciences Inc (DRUG) — Financial Flexibility Index

Latest as of March 2026: -2.48x

Bright Minds Biosciences Inc (DRUG) has a Financial Flexibility Index of -2.48x as of March 2026. Free cash flow of $-9.50 Million (operating CF $-9.50 Million minus capex $4.18) represents -2% of total liabilities ($3.83 Million). Check Bright Minds Biosciences Inc (DRUG) strategic investment index to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-2.48x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-9.50 Million
Operating CF − Capex

Total Liabilities

$3.83 Million
USD

Capital Expenditures

$4.18
USD

Bright Minds Biosciences Inc Financial Flexibility Index (2019–2025)

Historical Financial Flexibility Index trend for Bright Minds Biosciences Inc across 7 annual periods. See working capital position of Bright Minds Biosciences Inc to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Bright Minds Biosciences Inc (2019–2025)

Year-by-year free cash flow to debt coverage for Bright Minds Biosciences Inc. For the full company profile including market capitalisation, see Bright Minds Biosciences Inc (DRUG) market capitalisation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -3.66x $-8.69 Million $-8.69 Million $2.38 Million ▼ -12.3%
2024 -3.26x $-1.85 Million $-1.85 Million $568.26K ▲ +87.0%
2023 -25.01x $-7.02 Million $-7.02 Million $280.86K ▼ -184.3%
2022 -8.80x $-13.59 Million $-13.59 Million $1.54 Million ▲ +23.2%
2021 -11.46x $-7.32 Million $-7.32 Million $638.57K ▼ -499.8%
2020 -1.91x $-288.39K $-288.39K $150.92K ▼ -67.0%
2019 -1.14x $-42.01K $-42.01K $36.71K
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities